# The Pristine Post-Market Study

Study · id `cardio:ct-nct05228132` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05228132](<https://clinicaltrials.gov/study/NCT05228132>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05228132

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.

## Technical summary

Registry record NCT05228132. Allocation not applicable; no masking; primary purpose treatment. Start 2022-05-16 (actual); primary completion 2022-09-21 (actual). Results posted on 2024-04-11.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 142 participants (enrolled count; ClinicalTrials.gov record NCT05228132, source copy `cardio:ctgov-nct05228132-2024-04-11`, retrieved 2026-10-26)
- Started: 2022-05-16 (actual) (ClinicalTrials.gov record NCT05228132, source copy `cardio:ctgov-nct05228132-2024-04-11`, retrieved 2026-10-26)
- Primary completion: 2022-09-21 (actual) (ClinicalTrials.gov record NCT05228132, source copy `cardio:ctgov-nct05228132-2024-04-11`, retrieved 2026-10-26)
- Completion: 2022-09-21 (actual) (ClinicalTrials.gov record NCT05228132, source copy `cardio:ctgov-nct05228132-2024-04-11`, retrieved 2026-10-26)
- Results first posted: 2024-04-11 (ClinicalTrials.gov record NCT05228132, source copy `cardio:ctgov-nct05228132-2024-04-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05228132, source copy `cardio:ctgov-nct05228132-2024-04-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05228132-2024-04-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Pristine Post-Market Study
- Condition: Kidney Failure, Chronic
- Condition: Hemodialysis Complication
- Condition: Hemodialysis Catheter Infection
- Condition: Hemodialysis Access Failure
- Condition: Central Venous Catheter Related Bloodstream Infection
- Condition: End Stage Renal Disease
- Intervention (Device): Pristine™ Long-Term Hemodialysis Catheter
- Lead sponsor: C. R. Bard
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: C. R. Bard (`cardio:org-c-r-bard`)

## Provenance

Content hash: 9267f12b92de6cd866deecd4a1e1ee618aa3aba90ad97b7b8411e053c94040fc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
